Table 1 HLA-matched patient characteristics, donor cells, and outcomes.

ESRD, end-stage renal disease; FSGS, focal segmental glomerulosclerosis; IgA, IgA nephropathy; DM, diabetes; SLE, systemic lupus erythematosus; PKD, polycystic kidney disease; CIN, chronic interstitial nephritis.

Patient no.	Age at Tx/sex	ESRD diagnosis	CD34⁺ cell dose (×10⁶/kg)	CD3⁺ cell dose (×10⁶/kg)	SCr: Last measure (mg/dl)	Duration of follow-up (months)	Duration off IS drugs (months)
1	48/M	Unknown	8	1	1.32	41*	36^†
2	39/F	FSGS	8	1	1.02	157	0
3	24/M	Dysplasia	13	1	1.62	152	0
4	52/M	Unknown	5	1	1.13	137	119
5	34/M	IgA	13	1	1.37	135	129
6	61/F	DM	12	1	1.30	130	0
7	23/F	SLE	17	10	5.70^‡,§	119*	12^†
8	33/M	Reflux	17	1	0.75	124	122^†
9	29/F	Unknown	18	1	1.05	121	0
10	52/F	PKD	14	1	0.90	120	109
11	37/F	IgA	14	1	2.40^§	111	63
12	36/F	PKD	10	1	1.20	107	101^†
13	26/M	Unknown	6	1	1.20	100	88
14	22/F	Unknown	14	1	0.86	100	88
15	40/F	IgA	10	1	1.13	98	48^\|\|
16	42/M	Type 1 DM	6	1	1.13	34*	23^†
17	30/M	CIN	6	1	5.77^‡,§	71	52
18	39/M	IgA	9	1	1.29	80	71^†
19	29/M	IgA	12	1	1.26	77	68
20	45/F	Unknown	14	1	1.00	72	59
21	62/F	IgA	12	1	0.74	68	60^†
22	54/F	Alport	4	1	1.00	65	50
23	49/M	DM	6	1	1.03	55	41
24	28/M	Reflux	6	1	1.55	63	38
25	37/M	IgA	7	1	1.30	48	34
26	43/M	Unknown	14	1	1.04	46	0
27	38/F	IgA	6	1	0.80	36	23^†
28	44/M	IgA	9	1	1.63	35	22^†
29	30/M	IgA	11	5	1.07	27	14^†
					Median (months)	80	48

*Deceased.

†No loss of chimerism.

‡SCr, serum creatinine concentration just before dialysis.

§Relapse of kidney disease without rejection.

||Acute rejection at four years off IS drug, returned to IS drug therapy. Duration of follow-up is to last SCr test. Patient nos. 7 and 29 were given 10 × 10⁶ and 5 × 10⁶ T cells/kg to increase chimerism levels. Patient nos. 1, 7, and 16 died in association with coronary artery disease, lupus-related stroke, and complications of morbid obesity and diabetes mellitus, respectively.